ライフサイエンスコーパス: trypanosomal

1 al least squares (PLS) modelling of the anti-trypanosomal activity of the sample extracts using the L

2 36 but does not require Sam50 or ATOM40, the trypanosomal analogue of the Tom40 import pore.

3 y and selectively inhibit TbcatB relative to trypanosomal and human homologues.

4 ls are first line drugs for the treatment of trypanosomal and leishmanial diseases.

5 hat caused markedly pronounced inhibition of trypanosomal and neoplastic cell growth and viability.

6 The trypanosomal cathepsin TbcatB is essential for parasite

7 lycerol, is an inhibitor of this enzyme in a trypanosomal cell-free system.

8 gical target for the development of new anti-trypanosomal chemotherapy.

9 used by the intracellular protozoan parasite Trypanosomal cruzi , and current drugs are lacking in te

10 hat VNI, a potent and selective inhibitor of trypanosomal CYP51 that we identified and structurally c

11 antitrypanosomal activity via inhibition of trypanosomal cysteine proteases, TbCatB and rhodesain, t

12 evaluation of inhibitors of leishmanial and trypanosomal dihydrofolate reductase.

13 toward using 1 as a starting point for anti-trypanosomal drug discovery, we report efforts to reduce

14 ibition in thiamine uptake, whereas the anti-trypanosomal drug, melarsoprol, failed to affect the upt

15 ggest that it could be a new target for anti-trypanosomal drugs.

16 "drug repurposing" approach, we tested anti-trypanosomal effects of carbazole-derived compounds call

17 uggest that these compounds exert their anti-trypanosomal effects, at least in part, by inhibition of

18 , influence on the catalytic activity of the trypanosomal enzyme and its human counterpart, and their

19 or S109L), as the homologous residues in the trypanosomal enzyme contribute to the previously unrecog

20 We also show that this trypanosomal enzyme is inhibited by known inhibitors of

21 Our characterization of this trypanosomal enzyme shows that it is possible to disting

22 h plasmodial helix 18, and Tc-18Hs-SAHH, the trypanosomal enzyme with human helix 18.

23 wn herein to be a selective inhibitor of the trypanosomal enzyme.

24 cellular retention confirming that MDDL is a trypanosomal ER localization signal.

25 cNAc-PI) is the second step of mammalian and trypanosomal glycosylphosphatidylinositol biosynthesis.

26 e formation of ICLs leading to inhibition of trypanosomal growth.

27 Hs-18Tc-SAHH, the human enzyme with trypanosomal helix 18, was also prepared but differed in

28 This protease may be related to TbMSP-B, a trypanosomal homologue of Leishmania major surface prote

29 f T. cruzi or a parasite-conditioned medium (trypanosomal immunosuppressive factor (TIF) to cultures

30 in Africa because they confer resistance to trypanosomal infection and protect from African sleeping

31 hagas' disease, become highly susceptible to trypanosomal infection.

32 Expression of the trypanosomal mitochondrial genome requires the insertion

33 g cascade to generate open reading frames in trypanosomal mitochondrial mRNAs.

34 The majority of trypanosomal mitochondrial pre-mRNAs undergo massive uri

35 ed by a polyclonal antibody made against the trypanosomal mitochondrial topo II enzyme.

36 The structure of a trypanosomal N-ribohydrolase in complex with a transitio

37 llular compartments in T. cruzi using either trypanosomal or mammalian signal sequences.

38 However, TAC40 does not colocalize with trypanosomal orthologs of ERMES components and, unlike M

39 pATOM36, a novel essential component of the trypanosomal outer membrane protein import system that i

40 ing a (13)C-labelled metabolome dataset from trypanosomal parasites.

41 ate immune response, and the pathobiology of trypanosomal parasites.

42 edge the first pharmacological validation of trypanosomal PDEs as drug targets.

43 rmacologically validate the highly conserved trypanosomal PDEs as potential drug targets.

44 Trypanosomal phosphodiesterases B1 and B2 (TbrPDEB1 and

45 of aristeromycin, possessed meaningful anti-trypanosomal properties has prompted a search of other 7

46 7-deazapurines with similar or improved anti-trypanosomal responses.

47 ial cofactor binding properties of human and trypanosomal SAHHs (Hs-SAHH and Tc-SAHH), within 5 A of

48 well as advances in the characterization of trypanosomal secretory machinery, provide a unique model

49 is the first characterization of a UP from a trypanosomal source despite this activity being observed

50 Excellent in vivo activity in the trypanosomal STIB900 mouse model was found for five of t

51 Comparison of apo and histidine-bound trypanosomal structures indicates substantial active-sit

52 ouple occupies a central position within the trypanosomal thiol metabolism and delivers electrons als

53 protein and identifies tSNAP(c) as a unique trypanosomal transcription factor.

54 cation of hitherto unknown m(1)A residues in trypanosomal tRNA.

55 f the UTP-bound and apo forms of the minimal trypanosomal TUTase, TbTUT4, which is composed solely of

56 ructural and biochemical analyses of a novel trypanosomal TUTase, TbTUT4, which represents a minimal

57 Furthermore, substantial differences between trypanosomal TyrRS and human homologs are promising for